ProCE Banner Activity

Daratumumab/Pom/Dex Salvage Beneficial in R/R MM Single Institution Retrospective Analysis

Slideset Download
Conference Coverage
Combination daratumumab/pomalidomide/dexamethasone produced deep responses and long PFS in patients with R/R MM, including those refractory to IMiDs and proteasome inhibitors.

Released: December 12, 2016

Expiration: December 11, 2017

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

Amgen, Inc.

Celgene

Incyte

Merck & Co., Inc.

Seagen